There are many examples of repurposed drugs. Fingolimod is one worth knowing.
Originally studied in the context of transplant rejection, researchers discovered its ability to reduce the immune system’s inflammatory response which they found to be remarkably relevant to multiple sclerosis (MS).
Here’s it’s Mechanism of Action:
MS involves the immune system mistakenly attacking the nervous system. Fingolimod works by trapping lymphocytes inside lymph nodes, preventing them from reaching the brain and spinal cord. It also crosses the blood-brain barrier, potentially helping preserve its integrity.
It became the first oral disease-modifying agent FDA-approved for relapsing-remitting MS which is a significant shift from the injectable treatments that came before it.
It isn’t without concerns though. Bradycardia after the first dose, increased infection risk, and rare cases of macular edema mean patients require careful monitoring. It also isn’t recommended during pregnancy.
But for patients with MS, having an oral option that demonstrably reduced relapse rates and slowed disability progression was a meaningful step forward.
MBH/PS